5 Oversold Biotech Stocks To Buy Right Now

4. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Number of Hedge Fund Holders: 33

14-day RSI Value: 23.6

An Overweight rating and $30 price target were maintained on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on March 13 by Jeffrey Hung at Morgan Stanley.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biotech company that develops and commercializes medicines addressing central nervous system disorders. It is based in San Diego, California.

There were 33 hedge funds long ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in the fourth quarter, with a total stake value of $1.9 billion.

Follow Acadia Pharmaceuticals Inc (NASDAQ:ACAD)